Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,372 questions · 3,874 findings · 666 reviews

No studies found 431 · 11.1%GRADE not reported 783 · 20.2%Very low 995 · 25.7%Low 909 · 23.5%Moderate 596 · 15.4%High 160 · 4.1%

Intervention not reported

Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐ dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High vs low dose Systolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High vs low dose Diastolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

Angiotensin receptor blocker (high‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Amantadine vs placebo

Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome

Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).

1 finding from 1 review

Riluzole vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Physiotherapy and occupational therapy vs placebo

Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Physiotherapy and occupational therapy vs placebo

Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments Functional Independence Measure (total). Scale from: 0 to 126. Higher scores indicate less disability · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Betamethasone vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review